Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

This achievement leverages the pain-relieving properties of cannabis without inducing mind-altering side effects. The ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Intra-articular corticosteroid injection is associated with a reduced use of pain medications, including opioid combinations, ...

Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline ...

Only around 1 in 10 common non-surgical and non-invasive treatments for lower back pain is effective, suggests a pooled data ...

"The need for non-opioid pain treatments has never been ... Latigo's goal is to provide effective, rapid-acting pain relief without the risk of addiction. For more information, please visit ...